Xisu Pharma-backed fund leads strategic round in AI organ-on-chip startup CellX (Yaosu)

创业邦 · wechat · 2026-11-19

AI drug discovery startup Yaosu (CellX) raised a new strategic round in the tens of millions of RMB from CSPC Guofang Fund and Shanghai SDIC Chuantou funds — notable because the backers are industrial and state capital rather than typical financial VCs.

CSPC, a pharma giant with tens of billions in annual revenue, had already validated Yaosu's tech in real R&D scenarios; the equity move extends the partnership from collaboration to capital-level synergy. The fund's total committed size is 1.01B RMB.

The article frames the deal against pharma's worsening R&D ROI ('Eroom's law'), where animal models create a translation gap to human response. Yaosu's 'AI + organ-on-chip' platform (OC-Plex chips, 3DCellPainting, multi-omics, DeepInsight analysis in a wet-lab/dry-loop cycle) aims to produce human-relevant data. Regulators are easing the path: FDA promotes NAMs and is phasing out mandatory animal testing, China's CDE launched a NAMs pilot, and Yaosu's platform entered FDA's ISTAND review channel in January.

The piece also cautions that strategic investment is only a starting point: Yaosu must convert resources into real business synergy, keep the platform open, and accumulate regulatory validation evidence before the route can become next-gen drug R&D infrastructure.

Original post →

More from Venture

Venture channel →